MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research to evaluate various intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main demo objectives were to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, though among the exploratory... https://geronimoj655wit8.atualblog.com/profile